Menu
GeneBe

SLC29A3

solute carrier family 29 member 3, the group of Solute carrier family 29

Basic information

Region (hg38): 10:71319258-71381423

Links

ENSG00000198246NCBI:55315OMIM:612373HGNC:23096Uniprot:Q9BZD2AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • H syndrome (Strong), mode of inheritance: AR
  • dysosteosclerosis (Supportive), mode of inheritance: AR
  • H syndrome (Supportive), mode of inheritance: AR
  • H syndrome (Strong), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Histiocytosis-lymphadenopathy plus syndromeARAllergy/Immunology/Infectious; Audiologic/Otolaryngologic; Dermatologic; EndocrineLipogranulomatous infiltration has been reported as benefiting from surgical interventions, radiotherapy, and medical treatment (eg, with cylophosphamide, prednisolone); Hormonal insufficiency, including hypogonadotropic hypogonadism, hypothyroidism, and growth hormone deficiency, may benefit from medical treatment; Individuals may manifest with early-onset hearing loss, and early recognition and treatment of hearing impairment may improve outcomes, including speech and language developmentAllergy/Immunology/Infectious; Audiologic/Otolaryngologic; Cardiovascular; Dermatologic; Endocrine; Gastrointestinal; Musculoskeletal16118898; 16631937; 16650224; 16155931; 16155931; 18940313; 19336477; 19175903; 19889517; 20140240; 20199414; 20199539; 20399510; 20619369; 21178579; 21888995; 22238637; 22356918; 22653152; 22875837; 22989030; 23058913; 23406517; 23530176; 23623699

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the SLC29A3 gene.

  • H syndrome (408 variants)
  • not provided (59 variants)
  • not specified (23 variants)
  • Inborn genetic diseases (19 variants)
  • SLC29A3-related condition (2 variants)
  • Gemcitabine response (1 variants)
  • Acanthosis nigricans (1 variants)
  • Dysosteosclerosis (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the SLC29A3 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
4
clinvar
88
clinvar
9
clinvar
101
missense
4
clinvar
4
clinvar
192
clinvar
5
clinvar
7
clinvar
212
nonsense
1
clinvar
3
clinvar
1
clinvar
5
start loss
0
frameshift
15
clinvar
15
inframe indel
4
clinvar
4
splice donor/acceptor (+/-2bp)
3
clinvar
3
clinvar
6
splice region
1
3
8
3
15
non coding
17
clinvar
25
clinvar
18
clinvar
60
Total 23 10 218 118 34

Highest pathogenic variant AF is 0.0000788

Variants in SLC29A3

This is a list of pathogenic ClinVar variants found in the SLC29A3 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
10-71319279-G-C H syndrome Uncertain significance (Jan 13, 2018)300355
10-71319287-C-T H syndrome Uncertain significance (Jan 13, 2018)300356
10-71319303-C-T H syndrome Benign (Jan 13, 2018)877161
10-71319312-T-G H syndrome Likely pathogenic (Nov 08, 2022)2136876
10-71319318-C-T H syndrome Likely benign (Dec 11, 2023)1928581
10-71319324-G-C H syndrome Likely benign (Aug 30, 2023)2818547
10-71319390-G-A not specified Benign (Jan 24, 2024)1220931
10-71319472-T-C Benign (Nov 12, 2018)1272485
10-71319545-C-G Benign (Jun 19, 2021)1239908
10-71322739-C-T H syndrome Benign (Jan 21, 2024)1601707
10-71322744-T-C H syndrome Likely benign (May 18, 2021)1560200
10-71322750-C-T H syndrome Likely benign (Jun 18, 2021)1567092
10-71322752-A-G H syndrome Likely pathogenic (Oct 21, 2022)2441776
10-71322759-C-T H syndrome Uncertain significance (Jul 06, 2022)1019351
10-71322760-C-T H syndrome Likely benign (Nov 18, 2023)3018590
10-71322761-G-A H syndrome Uncertain significance (Apr 12, 2022)1515061
10-71322764-G-A H syndrome Uncertain significance (Dec 11, 2020)1357260
10-71322772-G-A H syndrome Likely benign (Oct 11, 2023)972053
10-71322775-C-A H syndrome • Inborn genetic diseases Uncertain significance (Jul 13, 2022)1387106
10-71322775-C-T H syndrome Likely benign (Jan 29, 2024)1102561
10-71322776-G-A H syndrome • Inborn genetic diseases Uncertain significance (Dec 19, 2023)581253
10-71322785-C-G H syndrome Uncertain significance (Jun 22, 2021)1492879
10-71322794-A-G H syndrome Uncertain significance (Dec 11, 2023)536248
10-71322805-CA-TG H syndrome Likely benign (Dec 26, 2023)1560152
10-71322806-A-G not specified • H syndrome Benign (Feb 01, 2024)130342

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
SLC29A3protein_codingprotein_codingENST00000373189 644128
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
1.29e-70.3721256941531257480.000215
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense-0.4772922701.080.00001733055
Missense in Polyphen10390.0151.14421056
Synonymous-1.491451241.170.000008941046
Loss of Function0.6521214.70.8167.28e-7172

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0007130.000713
Ashkenazi Jewish0.000.00
East Asian0.0001100.000109
Finnish0.000.00
European (Non-Finnish)0.0001510.000149
Middle Eastern0.0001100.000109
South Asian0.0005230.000490
Other0.0001630.000163

dbNSFP

Source: dbNSFP

Function
FUNCTION: Mediates both influx and efflux of nucleosides across the membrane (equilibrative transporter). Mediates transport of adenine, adenosine and uridine, as well as several nucleoside analog drugs, such as anticancer and antiviral agents, including cladribine, cordycepin, tubercidin and AZT. Does not transport hypoxanthine. {ECO:0000269|PubMed:15701636}.;
Pathway
Purine metabolism;Transport of vitamins, nucleosides, and related molecules;SLC-mediated transmembrane transport;Transport of small molecules;Pyrimidine metabolism;Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane (Consensus)

Recessive Scores

pRec
0.135

Intolerance Scores

loftool
0.595
rvis_EVS
0.43
rvis_percentile_EVS
77.29

Haploinsufficiency Scores

pHI
0.260
hipred
N
hipred_score
0.219
ghis
0.431

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
N
gene_indispensability_score
0.468

Gene Damage Prediction

AllRecessiveDominant
MendelianHighHighHigh
Primary ImmunodeficiencyHighHighHigh
CancerHighHighHigh

Mouse Genome Informatics

Gene name
Slc29a3
Phenotype
cellular phenotype; neoplasm; hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); immune system phenotype;

Gene ontology

Biological process
nucleoside transmembrane transport
Cellular component
lysosomal membrane;Golgi apparatus;integral component of membrane;late endosome membrane;intracellular membrane-bounded organelle
Molecular function
nucleoside transmembrane transporter activity;protein binding